Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00444665 · ClinicalTrials.gov registry record · Phase 4
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
A Phase 4 study of Glaucoma, sponsored by Alcon Research.
- Completed
- Registry status
- Phase 4
- Development phase
- 750
- Enrollment target
- 1
- Study location
NCT00444665: Completed Phase 4 study of Glaucoma, sponsored by Alcon Research.
NCT00444665 is a Phase 4 study of Glaucoma that has completed, run by Alcon Research. The registered enrollment target is 750 participants, below the 902-participant average among 92 other Glaucoma trials with a reported enrollment target (17% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00444665, a Phase 4 study of Glaucoma, has completed, sponsored by Alcon Research.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.
Conditions Studied
Interventions
- DRUG Travatan-Z
Study Locations (1)
Minnesota
- Fridley - Fridley
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2007-05 |
| Est. Completion | 2007-08 |
| Phase | Phase 4 |
What the finished NCT00444665 record still lists
NCT00444665 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, below the 902-participant average among 92 other Glaucoma trials with a reported enrollment target (17% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 1 intervention - of which Travatan-Z is the first listed.
NCT00444665 reports a single indexed study location in Minnesota.
Frequently Asked Questions
What is clinical trial NCT00444665 about?
NCT00444665 is a clinical study titled "Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy". Examine the safety, tolerability and efficacy of travoprost benzalkonium chloride (BAK) free ophthalmic solution compared to either latanoprost or bimatoprost monotherapy.
What is the current status of trial NCT00444665?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 750 participants. The study started on 2007-05. Estimated completion is 2007-08.
What conditions does trial NCT00444665 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00444665?
The interventions under investigation include: Travatan-Z (DRUG).
Who is sponsoring clinical trial NCT00444665?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00444665 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00444665's enrollment target sits among peer trials
750 7th of 92 higher than 86 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia